In the multivariable analysis , bevacizumab treatment ( hazard ratio [ HR ] , 3.00 ; P = .01 ) and age ( HR , 1.06 ; P = .02 ) were significantly associated with the risk of ATE ; whereas age ( HR , 1.05 ; P = .01 ) and VTE risk score ( HR , 1.83 ; P = .03 ) were significantly associated with the risk of VTE .